Get the latest tech news
OneCell Diagnostics bags $16M to help limit cancer reoccurrence using AI
OneCell Diagnostics has secured $16 million in a Series A round as it aims to limit cancer recurrence using AI advancements along with scientific ways.
Enter OneCell Diagnostics, a genomics-based startup in precision oncology, that aims to help cancer survivors limit reoccurrence instances through its proprietary cell biopsy technology. The startup, which has served nearly 10,000 patients in India and is looking to replicate its early Indian success in the U.S., has developed its in-house blood-based biopsy testing that helps detect cancer’s reoccurrence through circulating tumor cells. This helps provide better diagnosis, with at least 100 times more information than the current liquid biopsy testing, which largely revolves around cell-free DNA and ctDNA, said co-founder and CEO Mohan Uttarwar.
Or read this on TechCrunch